Business Description
Quantum BioPharma Ltd
NAICS : 541710
SIC : 3741
ISIN : CA35954B1076
Share Class Description:
QNTM: Ordinary Shares - Class B (Sub Voting)Total Employee Number:
7Description
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.25 | |||||
Equity-to-Asset | 0.04 | |||||
Debt-to-Equity | 1.46 | |||||
Debt-to-EBITDA | -0.03 | |||||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 40.1 | |||||
3-Year EPS without NRI Growth Rate | 53 | |||||
3-Year FCF Growth Rate | 62.5 | |||||
3-Year Book Growth Rate | -67.3 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 29.15 | |||||
9-Day RSI | 33.72 | |||||
14-Day RSI | 36.83 | |||||
3-1 Month Momentum % | 27.24 | |||||
6-1 Month Momentum % | -43.69 | |||||
12-1 Month Momentum % | -82.36 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.63 | |||||
Quick Ratio | 0.63 | |||||
Cash Ratio | 0.28 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -87.3 | |||||
Shareholder Yield % | -30.95 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -599 | |||||
ROA % | -218.92 | |||||
ROIC % | -121.03 | |||||
3-Year ROIIC % | -81.22 | |||||
ROC (Joel Greenblatt) % | -7556.68 | |||||
ROCE % | -877.18 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 30.9 | |||||
EV-to-EBIT | -0.44 | |||||
EV-to-EBITDA | -0.44 | |||||
EV-to-FCF | -2.44 | |||||
Earnings Yield (Greenblatt) % | -227.27 | |||||
FCF Yield % | -29 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:QNTM
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Quantum BioPharma Ltd Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -8.25 | ||
| Beta | 0.6476 | ||
| 3-Year Sharpe Ratio | -0.38 | ||
| 3-Year Sortino Ratio | -0.59 | ||
| Volatility % | 92.85 | ||
| 14-Day RSI | 36.83 | ||
| 14-Day ATR ($) | 0.375414 | ||
| 20-Day SMA ($) | 3.545 | ||
| 12-1 Month Momentum % | -82.36 | ||
| 52-Week Range ($) | 2.07 - 31.9141 | ||
| Shares Outstanding (Mil) | 6.4 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Quantum BioPharma Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Quantum BioPharma Ltd Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-06 | In 109 days | ||
| General meeting for 2025 | 2026-09-25 | In 67 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 17 days | ||
| First quarter earnings results for 2025 | 2026-05-06 | 5.36 (+2.49%) | ||
| Annual report for 2025 | 2026-03-26 | 4.35 (-8.81%) | ||
| Third quarter earnings results for 2025 | 2025-11-06 | 9.00 (+0.22%) | ||
| Unbuzzd Wellness Investor Webinar | 2025-10-30 16:15 | 12.85 (-0.85%) | ||
| General meeting for 2024 | 2025-09-26 | 17.07 (+0.41%) | ||
| Second quarter earnings results for 2025 | 2025-08-06 | 24.57 (-8.56%) | ||
| 0.0153846:1 Stock Split | 2024-08-15 | 5.84 (-4.56%) |
Show
Entries
Quantum BioPharma Ltd Frequently Asked Questions
What is Quantum BioPharma Ltd(QNTM)'s stock price today?
The current price of QNTM is $3.09. The 52 week high of QNTM is $31.91 and 52 week low is $2.07.
When is next earnings date of Quantum BioPharma Ltd(QNTM)?
The next earnings date of Quantum BioPharma Ltd(QNTM) is 2026-08-06 Est..
Does Quantum BioPharma Ltd(QNTM) pay dividends? If so, how much?
Quantum BioPharma Ltd(QNTM) does not pay dividend.
Guru Commentaries on NAS:QNTM
No articles.
Press Release
Articles on Quantum BioPharma Ltd
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers